A Study of Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The blinded phase only will be described in this record. Participants will be randomized in a 4:1 ratio to receive GWP42003-P or matching placebo. The hypothesis is that levels of stiripentol (STP) or valproate (VPA) may be altered (increased or decreased) as a result of using GWP42003-P.
Epistemonikos ID: 219fae91e95c73f7c97e8a05854e3c1b2967f2bb
First added on: May 12, 2024